NCT01266447 2019-08-08
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
The University of Texas Health Science Center at San Antonio